Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corteva (CTVA) Change in Account Payables (2020 - 2025)

Corteva has reported Change in Account Payables over the past 6 years, most recently at $108.0 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $108.0 million for Q4 2025, down 73.2% from a year ago — trailing twelve months through Dec 2025 was $231.0 million (up 300.87% YoY), and the annual figure for FY2025 was $231.0 million, up 300.87%.
  • Change in Account Payables for Q4 2025 was $108.0 million at Corteva, down from $479.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for CTVA hit a ceiling of $1.0 billion in Q4 2022 and a floor of -$2.5 billion in Q2 2023.
  • Median Change in Account Payables over the past 5 years was $197.0 million (2022), compared with a mean of $39.3 million.
  • Biggest five-year swings in Change in Account Payables: surged 450.0% in 2021 and later crashed 2908.54% in 2023.
  • Corteva's Change in Account Payables stood at $567.0 million in 2021, then soared by 77.95% to $1.0 billion in 2022, then crashed by 45.0% to $555.0 million in 2023, then dropped by 27.39% to $403.0 million in 2024, then plummeted by 73.2% to $108.0 million in 2025.
  • The last three reported values for Change in Account Payables were $108.0 million (Q4 2025), $479.0 million (Q3 2025), and -$166.0 million (Q2 2025) per Business Quant data.